Drug principal Dr Reddy's Laboratories Thursday announced the launch of Sevelamer Carbonate for oral suspension, used for controlling serum phosphorus in patients with continual kidney disease on dialysis, in the US market.
The newly launched product is within the strengths of 0.eight g and a couple of.four g packets, and is a therapeutic equal ordinary edition of Renvela (sevelamer carbonate) for oral suspension, authorised by means of the us meals and Drug Administration (USFDA), Dr Reddy's Laboratories said in a BSE filing.
Quoting IMS health data, the company spoke of the Renvela brand and customary had US income of approximately USD a hundred and one million for the most fresh 365 days ending in October 2018.
Shar es of Reddy's Laboratories were trading 0.sixty four per cent lower at Rs 2,601.forty five apiece on BSE.
0 comentários:
Postar um comentário